Provided by Tiger Trade Technology Pte. Ltd.

BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON

0.6217
+0.00941.54%
Post-market: 0.6126-0.0091-1.46%16:00 EDT
Volume:11.68K
Turnover:7K
Market Cap:25.38M
PE:-0.61
High:0.6300
Open:0.6300
Low:0.6191
Close:0.6123
52wk High:1.83
52wk Low:0.5120
Shares:40.83M
Float Shares:27.26M
Volume Ratio:0.36
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0237
EPS(LYR):-1.6400
ROE:-52.38%
ROA:-18.99%
PB:0.44
PE(LYR):-0.38

Loading ...

Company Profile

Company Name:
BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
14
Office Location:
20400 Century Boulevard,Suite 210,Germantown,Maryland,United States
Zip Code:
20874
Fax:
- -
Introduction:
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

Directors

Name
Position
Robin Wright
Chairman of the Board and Independent Director
William Enright
Chief Executive Officer and Director
Alex Hammacher
Non-Executive Director
Anne M. Phillips
Independent Director
Joseph C. Scheeren
Independent Director
Karen T. Dawes
Independent Director
Pierre A. Morgon
Independent Director

Shareholders

Name
Position
William Enright
Chief Executive Officer and Director
Leon Hooftman
Chief Medical Officer